This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Psychemedics Stock (NASDAQ:PMD) Get Psychemedics alerts:Sign Up Key Stats Today's Range$2.46▼$2.7750-Day Range$2.32▼$3.2152-Week Range$1.63▼$3.25Volume113,627 shsAverage VolumeN/AMarket Capitalization$16.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. Read More Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMD Stock News HeadlinesPsychemedics Releases 2025 Workforce Insights ReportJune 16, 2025 | globenewswire.comPsychemedics Named “Most Innovative Drug Testing Company of the Year”May 16, 2025 | globenewswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 10 at 2:00 AM | Porter & Company (Ad)Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing InsightsMarch 3, 2025 | markets.businessinsider.comPsychemedics announces reverse stock split, forward stock splitDecember 3, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | gurufocus.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | globenewswire.comPsychemedics reminds stockholders to cast votes for Annual MeetingNovember 19, 2024 | markets.businessinsider.comSee More Headlines PMD Stock Analysis - Frequently Asked Questions How were Psychemedics' earnings last quarter? Psychemedics Corporation (NASDAQ:PMD) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.09) earnings per share for the quarter. The business earned $5.20 million during the quarter. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD). Company Calendar Last Earnings11/12/2024Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealthcare Current SymbolNASDAQ:PMD CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees140Year Founded1985Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$19.68 million Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book3.18Miscellaneous Outstanding Shares6,120,000Free Float5,266,000Market Cap$16.34 million OptionableNot Optionable BetaN/A Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PMD) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTexit: The $1.4 trillion reason why tech is fleeing Cali for TexasThe state of Texas recently made a critical change to its laws… In a quest to become the AI data center cap...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Psychemedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
